Patents Assigned to Pieris AG
-
Publication number: 20160280747Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. A like immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.Type: ApplicationFiled: April 6, 2016Publication date: September 29, 2016Applicant: Pieris AGInventors: ARNE SKERRA, Gerald Beste, Frank Schmidt, Thomas Stibora
-
Publication number: 20160256525Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: December 28, 2015Publication date: September 8, 2016Applicant: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 9260492Abstract: Described are specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins include muteins of a lipocalin protein, such as lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: GrantFiled: November 15, 2011Date of Patent: February 16, 2016Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Kristian Jensen
-
Patent number: 9221885Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) also known as CD152, which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: GrantFiled: December 2, 2011Date of Patent: December 29, 2015Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Arne Skerra
-
Patent number: 9221887Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: September 14, 2012Date of Patent: December 29, 2015Assignee: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 9212208Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: January 29, 2009Date of Patent: December 15, 2015Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
-
Patent number: 8986951Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: GrantFiled: June 8, 2011Date of Patent: March 24, 2015Assignee: Pieris AGInventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
-
Publication number: 20140288008Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicants: Daiichi Sankyo Company, Limited, Pieris AGInventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
-
Publication number: 20140080177Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.Type: ApplicationFiled: August 20, 2013Publication date: March 20, 2014Applicant: Pieris AGInventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
-
Patent number: 8536307Abstract: The invention relates to the production of novel proteins exhibiting binding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using genetic engineering methods. Like immunoglobulin, the anticalin thus obtained can be used to identify or bind molecular structures.Type: GrantFiled: March 19, 2012Date of Patent: September 17, 2013Assignee: Pieris AGInventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
-
Patent number: 8313924Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: August 1, 2007Date of Patent: November 20, 2012Assignee: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 8158753Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.Type: GrantFiled: January 5, 2010Date of Patent: April 17, 2012Assignee: Pieris AGInventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
-
Patent number: 7892827Abstract: The present invention relates to a compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein the compound exhibits a synergistic mode of action in that the compound: (a) increases T cell priming or T cell expansion or the generation of memory T cells by blocking of CTLA-4, and (b) enhances effector T cell activity in tumor tissue or lymphoid tissue by blocking of CTLA-4. The compound of the invention can be a protein, a small organic molecule, a peptide, or a nucleic acid.Type: GrantFiled: November 25, 2005Date of Patent: February 22, 2011Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Steffen Schlehuber, Martin Pöhlchen, Arne Skerra
-
Patent number: 7893208Abstract: The present invention relates to novel muteins derived from tear lipocalin or a homologue thereof. In particular, the invention relates to a mutein of human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.Type: GrantFiled: August 19, 2009Date of Patent: February 22, 2011Assignee: Pieris AGInventors: Arne Skerra, Steffen Schlehuber
-
Patent number: 7723476Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.Type: GrantFiled: September 13, 2005Date of Patent: May 25, 2010Assignee: Pieris AGInventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
-
Patent number: 7691970Abstract: The present invention relates to novel muteins derived from a bilin-binding protein (BBP) that binds a given target, for example a macromolecular target, with detectable affinity. In particular, the invention relates to a mutein of the bilin-binding protein of Pieris brassicae. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.Type: GrantFiled: August 25, 2003Date of Patent: April 6, 2010Assignee: Pieris AGInventors: Arne Skerra, Steffen Schlehuber
-
Patent number: 7585940Abstract: The present invention relates to novel muteins derived from tear lipocalin or a homologue thereof. In particular, the invention relates to a mutein of human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.Type: GrantFiled: August 24, 2004Date of Patent: September 8, 2009Assignee: Pieris AGInventors: Arne Skerra, Steffen Schlehuber
-
Patent number: 7252998Abstract: Disclosed is a method for generating a mutein of a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat ?2-microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having detectable affinity to a given target. The method comprises the step of subjecting the protein to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, resulting in one or more mutein(s) of the protein. Also disclosed are muteins obtainable by this method.Type: GrantFiled: September 18, 2002Date of Patent: August 7, 2007Assignee: Pieris AGInventors: Arne Skerra, Steffen Schlehuber
-
Patent number: 7250297Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using genetic engineering methods. A like immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.Type: GrantFiled: September 25, 1998Date of Patent: July 31, 2007Assignee: Pieris AGInventors: Gerald Beste, Thomas Stibora, Arne Skerre, Frank Schmidt